Edgewise Therapeutics

EWTX47

$17.52arrow_drop_up0.28%$0.05

EWTX47

$17.52

arrow_drop_up0.28%$0.05

Performance History

Key Stats
Open	$18.11
Prev. Close	$17.93
EPS	-1.53
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	17.81	18.11
52 Week Range	5.12	23.50

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.53

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Edgewise Therapeutics (EWTX)

Edgewise Therapeutics, Inc. (EWTX) is a biopharmaceutical company focused on the development of small molecule therapies for the treatment of musculoskeletal diseases. The company's lead product candidate, EWTX-001, is a novel, oral small molecule inhibitor of the integrin alpha-v-beta-8 (αvβ8) receptor. By inhibiting αvβ8, EWTX-001 has the potential to modulate the transforming growth factor beta (TGF-β) pathway, which plays a critical role in the development and progression of fibrotic, inflammatory, and degenerative diseases of the musculoskeletal system.

The potential of EWTX-001 lies in its ability to selectively target αvβ8 without affecting other integrin receptors, thereby minimizing off-target effects. Preclinical studies have shown promising results, demonstrating the potential of EWTX-001 to inhibit fibrosis, reduce inflammation, and promote tissue regeneration. In addition, EWTX-001 has demonstrated a favorable safety profile in preclinical studies, further supporting its potential as a therapeutic option for musculoskeletal diseases.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Kevin Koch Ph.D.
Headquarters: Boulder
Employees: 74
Exchange: NASDAQ

Keep an eye on Edgewise Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Edgewise Therapeutics's (EWTX) price per share?

The current price per share for Edgewise Therapeutics (EWTX) is $17.52. The stock has seen a price change of $0.05 recently, indicating a 0.29% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Edgewise Therapeutics (EWTX)?

For Edgewise Therapeutics (EWTX), the 52-week high is $23.5, which is 34.13% from the current price. The 52-week low is $5.12, the current price is 242.19% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Edgewise Therapeutics (EWTX) a growth stock?

Edgewise Therapeutics (EWTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 72 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Edgewise Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Edgewise Therapeutics (EWTX) stock price performance year to date (YTD)?

As of the latest data, Edgewise Therapeutics (EWTX) has a year-to-date price change of 59.27%. Over the past month, the stock has experienced a price change of 9.02%. Over the last three months, the change has been -0.51%. Over the past six months, the figure is 3.06%.

help

Is Edgewise Therapeutics (EWTX) a profitable company?

Edgewise Therapeutics (EWTX) has a net income of -$100.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$114.36M. Furthermore, the EBITDA is -$134.29M.

help

What is the market capitalization of Edgewise Therapeutics (EWTX)?

Edgewise Therapeutics (EWTX) has a market capitalization of $1.64B. The average daily trading volume is 757.09K, indicating the stock's liquidity and investor engagement.